Advertisement

Seminars in Immunopathology

, Volume 39, Issue 3, pp 327–331 | Cite as

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

  • Franck Carbonnel
  • Emilie Soularue
  • Clélia Coutzac
  • Nathalie Chaput
  • Christine Mateus
  • Patricia Lepage
  • Caroline RobertEmail author
Review

Abstract

Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident Treg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.

Keywords

Inflammatory Bowel Disease Treg Cell Ipilimumab Abatacept Intestinal Inflammation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hodi FS, O’Day SJ, Sosman JA et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526CrossRefPubMedGoogle Scholar
  3. 3.
    Lynch TJ, Bondarenko I, Luft A et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054CrossRefPubMedGoogle Scholar
  4. 4.
    Hodi FS, Mihm MC, Soiffer RJ et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100(8):4712–4717CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105(8):3005–3010CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yang JC, Hughes M, Kammula U et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fong L, Kwek SS, O’Brien S et al (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2):609–615CrossRefPubMedGoogle Scholar
  8. 8.
    Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tarhini AA, Cherian J, Moschos SJ et al (2012) Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30(3):322–328CrossRefPubMedGoogle Scholar
  10. 10.
    Kirkwood JM, Lorigan P, Hersey P et al (2010) Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16(3):1042–1048CrossRefPubMedGoogle Scholar
  11. 11.
    Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Calabrò L, Morra A, Fonsatti E et al (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14(11):1104–1111CrossRefPubMedGoogle Scholar
  13. 13.
    McNeel DG, Smith HA, Eickhoff JC et al (2012) Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 61(7):1137–1147CrossRefPubMedGoogle Scholar
  14. 14.
    Aglietta M, Barone C, Sawyer MB et al (2014) A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol 25(9):1750–1755CrossRefPubMedGoogle Scholar
  15. 15.
    Sangro B, Gomez-Martin C, De la Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59(1):81–88CrossRefPubMedGoogle Scholar
  16. 16.
    Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697CrossRefPubMedGoogle Scholar
  17. 17.
    Beck KE et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283–2289CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gupta A, De Felice KM, Loftus EV, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42(4):406–417CrossRefPubMedGoogle Scholar
  19. 19.
    Marthey L et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395–401CrossRefPubMedGoogle Scholar
  20. 20.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) Keynote-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMedGoogle Scholar
  21. 21.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefPubMedGoogle Scholar
  22. 22.
    Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486CrossRefPubMedGoogle Scholar
  23. 23.
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114–1123CrossRefPubMedGoogle Scholar
  24. 24.
    Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB (2012) Abatacept for Crohn’s disease and ulcerative colitis. Gastroenterology 143(1):62–69CrossRefPubMedGoogle Scholar
  25. 25.
    Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray SS, Nadler LM (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262(5135):909–911CrossRefPubMedGoogle Scholar
  26. 26.
    Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366(6450):76–79CrossRefPubMedGoogle Scholar
  27. 27.
    Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600–603CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465CrossRefPubMedGoogle Scholar
  29. 29.
    Mc Coy KD, Le Gros G (1999) The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 77(1):1–10CrossRefGoogle Scholar
  30. 30.
    Sansom DM, Walker LS (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 212:131–148CrossRefPubMedGoogle Scholar
  31. 31.
    Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210(9):1685–1693CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, Qureshi OS, Sansom DM, Walker LS (2012) Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol 189(3):1118–1122CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112(19):6140–6145CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1(1):32–42CrossRefPubMedGoogle Scholar
  35. 35.
    Peggs KS (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206(8):1717–25Google Scholar
  36. 36.
    Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R (2013) Depleting tumor-specific tregs at a single site eradicates disseminated tumors. J Clin Invest 123(6):2447–2463CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, Sharpe AH, Powrie F (2006) Blockade of CTLA-4 on CD4 + CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177(7):4376–4383CrossRefPubMedGoogle Scholar
  40. 40.
    Barnes MJ, Griseri T, Johnson AM et al (2013) CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 6(2):324–334CrossRefPubMedGoogle Scholar
  41. 41.
    Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, Stappenbeck TS, Hsieh CS (2011) Peripheral education of the immune system by colonic commensal microbiota. Nature 478(7368):250–254CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, Laerdahl JK, Stade B, Forster M, Schreiber S, Weir D, Leichtner AM, Franke A, Blumberg RS (2015) Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut 64(12):1889–1897CrossRefPubMedGoogle Scholar
  43. 43.
    Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schäffer AA, Grüning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LS, Sansom DM, Grimbacher B (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410–1416CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623–1627CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Maynard CL, Elson CO, Hatton RD, Weaver CT (2012) Reciprocal interactions of the intestinal microbiota and immune system. Nature 489(7415):231–241CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Jostins L (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422):119–24Google Scholar
  47. 47.
    Chassaing B, Darfeuille-Michaud A (2011) The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140(6):1720–1728CrossRefPubMedGoogle Scholar
  48. 48.
    Taurog JD, Richardson JA, Croft JT, Zhou M, Simmons WA et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364CrossRefPubMedGoogle Scholar
  49. 49.
    Iqbal N, Oliver JR, Wagner FH, Lazenby AS, Elson CO, Weaver CT (2002) T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 195:71–84CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH et al (1998) CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 187:855–864CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Vernier G, Sendid B, Poulain D, Colombel JF (2004) Relevance of serologic studies in inflammatory bowel disease. Curr Gastroenterol Rep 6(6):482–487CrossRefPubMedGoogle Scholar
  52. 52.
    Calderón-Gómez E, Bassolas-Molina H, Mora-Buch R, Dotti I, Planell N, Esteller M, Gallego M, Martí M, Garcia-Martín C, Martínez-Torró C, Ordás I, Singh S, Panés J, Benítez-Ribas D, Salas A (2016) Commensal-specific CD4(+) cells from patients with Crohn’s disease have a T-helper 17 inflammatory profile. Gastroenterology 151(3):489–500CrossRefPubMedGoogle Scholar
  53. 53.
    Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131(1):33–45CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Dubin K et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Vétizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Franck Carbonnel
    • 1
    • 2
  • Emilie Soularue
    • 1
    • 2
  • Clélia Coutzac
    • 3
  • Nathalie Chaput
    • 3
    • 4
  • Christine Mateus
    • 5
  • Patricia Lepage
    • 6
  • Caroline Robert
    • 5
    Email author
  1. 1.Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Le Kremlin BicêtreFrance
  2. 2.Université Paris-Sud, Faculté de MédecineLe Kremlin BicêtreFrance
  3. 3.Gustave Roussy, Laboratoire d’Immunomonitoring en Oncologie, and CNRS-UMS 3655 and INSERM-US23VillejuifFrance
  4. 4.Université Paris-Sud, Faculté de pharmacie, Chatenay-MalabryChâtenay-MalabryFrance
  5. 5.Gustave Roussy, Département de Médecine, Service de Dermatologie, et Université Paris-Sud VillejuifVillejuifFrance
  6. 6.Micalis Institute, INRA, AgroParisTechUniversité Paris-SaclayJouy-en-JosasFrance

Personalised recommendations